Calls for public enquiry after dozens of cancer patients overprescribed chemotherapy for years

Independent Membership

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today.

Join today

Already a member? Log in

Dozens of cancer patients at an NHS trust were given a chemotherapy drug for years longer than they should have been, a shocking new report has found, sparking calls for a public inquiry.

More than 40 patients say they suffered life-changing effects when they were needlessly given temozolomide, a highly toxic cancer drug, at the University Hospitals Coventry and Warwickshire NHS Trust (UHCW).

In some cases, the treatment, known as TMZ, continued needlessly for more than a decade, even though it should normally be used for only six months.

The Royal College of Physicians (RCP), which looked into the scandal, says extended treatment was given without evidence; concerns around consent; incorrect diagnoses and serious failures of clinical oversight.

Its investigation was prompted by concerns over the practice of a recently retired consultant clinical oncologist, identified only as Dr Y, who was employed by the trust from 1996 to 2024.

The report says 15 of the 20 cases it reviewed were “unsatisfactory overall”, five required improvement, and none was rated as good practice.

“There was no evidence of effective challenge at any stage from the wider multidisciplinary team, including nursing and pharmacy teams,” the document concludes, adding: “Some very unusual therapeutic decisions appear not to have been challenged.”

In the worst example, a patient had over 100 cycles of TMZ before it was identified that they had a slow-growing, low-grade brain tumour. The patient later developed acute myeloid leukaemia, a fast-growing blood cancer. Developing new cancers is a known risk of using drugs such as TMZ.

Gayle Bodinnar had more than 150 rounds of the drug over at least 12 years, which she says left her housebound.

The report also found concerns in all 20 cases about how consent was obtained from patients for the treatment and how it was explained to them.

“In some cases, there was no documentation of consent where this would be expected. Where they were seen, consent forms were often of poor quality and lacked relevant information.”

Becky Jones was 21 when she was told she had a grade 4 glioblastoma – an aggressive brain tumour - and only six to 12 months to live. She received more than 100 cycles of temozolomide over more than a decade before independent experts concluded that she had never had a brain tumour.

Ms Jones said: “For years, I questioned why I was still being given chemotherapy when my scans were stable, but I was repeatedly told that without it I would die.”

The Royal College report recommends an independent review for every living patient who received more than 12 monthly cycles of temozolomide.

It also says the NHS trust should consider reviewing the large number of dead patients who received the same non-standard treatment.

Ms Jones said: “Seeing the RCP independently confirm serious failings is validating, although it is incredibly painful to see how many opportunities there were to protect us.

“I now need a full and honest explanation of what happened to me.

“This has shaped my entire adult life. I lost career opportunities, family moments and years to treatment and the constant fear that I was going to die.

“The report cannot give me that time back, but an independent review may finally provide the answers and accountability I have been fighting for - and help ensure no other patient has to fight this hard to be heard.”

Patients who are suing the trust say other effects included crippling fatigue, confusion, sickness and seizures, and left them unable to pursue normal day-to-day activities.

David Bown, who was diagnosed with a brain tumour in 2016, suffered permanent neurological damage following complications after surgery and was later treated with TMZ for more than eight years. His condition has since deteriorated further and he has now lost the ability to speak.

Stephen Bown, his father, said what had happened to his son had been devastating.

“Before, he was working full-time, playing football, coaching and managing an under-9s football team and living his own life. His condition has now deteriorated to the point where he can no longer speak clearly and he depends on us completely.

“David can’t tell people himself what this has done to him any more, so I have to do that for him.

“These findings finally recognise the seriousness of what happened to patients like David, but there are still so many questions about how it was allowed to happen.”

The report says the potential harm caused was considered severe in six cases.

“There was a lack of an individualised approach taken in the treatment of these patients. For example, grade 3 tumours were treated the same as grade 4 glioblastomas,” it says.

“There were multiple examples of extended treatment with TMZ (and, in some cases, other second-line chemotherapy drugs) being continued despite clear evidence of toxicity and/or deterioration in the patient’s condition, with little or no evidence of benefit.”

It adds: “Particularly protracted courses of TMZ, and in some cases the patient’s young age during the treatment, meant that they were put at significant risk of long-term side effects. This included the risk of secondary cancer later in life.”

UHCW, which has been approached for comment, spent more than £3.6m on temozolomide between 2007 and 2023 – over 10 times that of comparable NHS hospitals.

Professor Andy Hardy, who is chief executive, and trust chair Sue Noyes at the University Hospitals Coventry and Warwickshire NHS Trust (UHCW) said in a statement that meaningful action has been taken to address the concerns detailed in a Royal College of Physicians (RCP) report, published on Wednesday.

“We are deeply sorry to all the patients and families affected by failures within our neuro-oncology service under the care of retired clinical oncologist Ian Brown,” Prof Hardy and Ms Noyes said in a statement.

“We recognise the concern, distress and loss of trust experienced by those who placed their faith in us during some of the most difficult moments of their lives.”

The statement said the RCP report showed how patients’ treatment “was prolonged beyond accepted national guidance, and that opportunities were missed to challenge and oversee these clinical decisions sooner.

“It also, distressingly, shows that some patients experienced harm because of the care they received.

“This is far below the standards our patients deserve and that we expect. We let you down, and for that we offer our sincere apologies.”

The pair said the trust has extended its historical review back to 2005, when national guidance for drug temozolomide (TMZ) was first published, “to ensure affected patients are identified and supported”

Original source Calls for public enquiry after dozens of cancer patients overprescribed chemotherapy for years

Back to home